À retenir
In a secondary analysis of the DEVOTE insulin trial, higher day-to-day variability in fasting self-measured glucose was associated with severe hypoglycaemia (HR 4.11, 95% CI 3.15 to 5.35) and all-cause mortality (HR 1.58, 95% CI 1.23 to 2.03) before adjustment. Both links held after adjustment, but the link with major cardiovascular events did not, and the design shows association only.
Study design
Essai randomisé
Reading basis
Published abstract
Reading focus
Comparator & uncertainty
Cette explication éditoriale existe en anglais, chinois simplifié et chinois traditionnel. Cette interface affiche la lecture en anglais.
Question de recherche
Blood sugar that bounces from day to day may carry its own risks beyond the average level. The authors used the DEVOTE trial, which compared insulin degludec with insulin glargine U100 in type 2 diabetes at high cardiovascular risk, to ask whether day-to-day fasting glucose variability relates to severe hypoglycaemia and cardiovascular outcomes.
Population et méthode
Secondary analysis of DEVOTE, a double-blind, randomised, event-driven, treat-to-target trial. Variability was the standard deviation of pre-breakfast self-measured blood glucose (SMBG): each month only the three readings recorded before contact with the site were used, log-transformed, and the variances averaged across months before taking the square root. Associations with severe hypoglycaemia, major adverse cardiovascular events (MACE) and all-cause mortality were analysed in the pooled trial population with Cox proportional hazards models, with sensitivity analyses adjusting for baseline characteristics and most recent HbA1c. The abstract does not give the number of participants.
Résultats
The authors’ reported results. Read each estimate with its population and uncertainty.
- 1Before adjustment, higher variability was associated with severe hypoglycaemia (HR 4.11, 95% CI 3.15 to 5.35), MACE (HR 1.36, 95% CI 1.12 to 1.65) and all-cause mortality (HR 1.58, 95% CI 1.23 to 2.03).
- 2Doubling a patient's variability measure corresponded to a 2.7-fold risk of severe hypoglycaemia, 1.2-fold for MACE and 1.4-fold for all-cause mortality.
- 3The links with severe hypoglycaemia and all-cause mortality remained after adjustment; the abstract does not give those adjusted numbers.
- 4The link with MACE did not hold after adjusting for baseline characteristics with baseline HbA1c (HR 1.19, 95% CI 0.96 to 1.47) or most recent HbA1c (HR 1.21, 95% CI 0.98 to 1.49).
Limites et incertitude
- 1It is a secondary, observational analysis inside a randomised trial, so it cannot show that reducing variability would lower risk.
- 2Variability came from only three self-measured fasting readings per month, which may be noisy.
- 3Participants were people with type 2 diabetes at high cardiovascular risk, treated with basal insulin, so results may not apply to people with lower risk or on other treatments.
- 4Very low or high glucose or poorer health could drive both unstable readings and events, and adjustment may not remove that.
Mise en perspective
Large swings in fasting glucose from one morning to the next went along with more severe hypoglycaemia and deaths in this high-risk trial population. That makes steady readings worth discussing with your care team, but the study does not show how to achieve them. Do not change insulin doses on your own.
Vos données
If you check fasting glucose or wear a continuous glucose monitor, look at how much your morning readings spread across days, using the same meter or sensor and a consistent time. Share patterns with your clinician rather than reacting to a single reading.
Comprendre ce type de preuve
Randomisation can support causal inference, but check allocation, blinding, missing outcomes, follow-up and the actual comparator. A trial label alone does not establish high certainty.
Résumé structuré des auteurs English
Le résumé original en anglais est reproduit avec attribution sous la licence ouverte indiquée. Il s’agit d’une source, pas d’une interprétation MoveVitals. L’analyse préparée figure ci-dessus ; vérifiez les conclusions importantes dans la source.
Aims/hypothesis
The Trial Comparing Cardiovascular Safety of Insulin Degludec vs Insulin Glargine in Patients with Type 2 Diabetes at High Risk of Cardiovascular Events (DEVOTE) was a double-blind, randomised, event-driven, treat-to-target prospective trial comparing the cardiovascular safety of insulin degludec with that of insulin glargine U100 (100 units/ml) in patients with type 2 diabetes at high risk of cardiovascular events. This paper reports a secondary analysis investigating associations of day-to-day fasting glycaemic variability (pre-breakfast self-measured blood glucose [SMBG]) with severe hypoglycaemia and cardiovascular outcomes.
Methods
In DEVOTE, patients with type 2 diabetes were randomised to receive insulin degludec or insulin glargine U100 once daily. The primary outcome was the first occurrence of an adjudicated major adverse cardiovascular event (MACE). Adjudicated severe hypoglycaemia was the pre-specified secondary outcome. In this article, day-to-day fasting glycaemic variability was based on the standard deviation of the pre-breakfast SMBG measurements. The variability measure was calculated as follows. Each month, only the three pre-breakfast SMBG measurements recorded before contact with the site were used to determine a day-to-day fasting glycaemic variability measure for each patient. For each patient, the variance of the three log-transformed pre-breakfast SMBG measurements each month was determined. The standard deviation was determined as the square root of the mean of these monthly variances and was defined as day-to-day fasting glycaemic variability. The associations between day-to-day fasting glycaemic variability and severe hypoglycaemia, MACE and all-cause mortality were analysed for the pooled trial population with Cox proportional hazards models. Several sensitivity analyses were conducted, including adjustments for baseline characteristics and most recent HbA_(1c).
Results
Day-to-day fasting glycaemic variability was significantly associated with severe hypoglycaemia (HR 4.11, 95% CI 3.15, 5.35), MACE (HR 1.36, 95% CI 1.12, 1.65) and all-cause mortality (HR 1.58, 95% CI 1.23, 2.03) before adjustments. The increased risks of severe hypoglycaemia, MACE and all-cause mortality translate into 2.7-, 1.2- and 1.4-fold risk, respectively, when a patient's day-to-day fasting glycaemic variability measure is doubled. The significant relationships of day-to-day fasting glycaemic variability with severe hypoglycaemia and all-cause mortality were maintained after adjustments. However, the significant association with MACE was not maintained following adjustment for baseline characteristics with either baseline HbA_(1c) (HR 1.19, 95% CI 0.96, 1.47) or the most recent HbA_(1c) measurement throughout the trial (HR 1.21, 95% CI 0.98, 1.49).
Conclusions/interpretation
Higher day-to-day fasting glycaemic variability is associated with increased risks of severe hypoglycaemia and all-cause mortality.
Trial registration
ClinicalTrials.gov NCT01959529.
Sources et attribution
Day-to-day fasting glycaemic variability in DEVOTE: associations with severe hypoglycaemia and cardiovascular outcomes (DEVOTE 2).
Zinman B, Marso SP, Poulter NR, Emerson SS, Pieber TR, Pratley RE, Lange M, Brown-Frandsen K, Moses A, Ocampo Francisco AM, Barner Lekdorf J, Kvist K, Buse JB, DEVOTE Study Group.
Diabetologia · 2017-09-15
DOI: 10.1007/s00125-017-4423-z ↗PubMed · 28913575 ↗Europe PMC · Licence indiquée: cc by ↗Abstract © the original authors, reproduced under the recorded open licence. Translations support reading; use the English record to check terminology and numerical results. Our methodological interpretation is separate from the authors’ conclusions.
Interprétation éditoriale MoveVitals · contenu éducatif · aucune évaluation clinique individuelle enregistrée
Sources vérifiées 2026-11-01
Guides pratiques
À lire ensemble
Early time-restricted eating linked to more weight loss and lower insulin than late eating
Pooling 41 randomised trials (2287 participants, median intervention 8 weeks), time-restricted eating was associated with 2.15 kg lower body weight than usual diets (95% CI -2.56 to -1.74), and eating early beat eating late by 1.15 kg (95% CI -1.86 to -0.45). Most trials were short, only 6 study arms tested early eating, and the outcomes were body and blood measures, not heart attacks or deaths.
BMJ Medicine
An 8 a.m. to 4 p.m. eating window added to calorie cutting gave no clear extra weight loss
Among 139 patients with obesity on a calorie-restricted diet, adding an eating window of 8:00 a.m. to 4:00 p.m. led to a mean 12-month weight change of -8.0 kg, versus -6.3 kg with calorie restriction alone. The net difference of -1.8 kg (95% CI -4.0 to 0.4; P = 0.11) was not statistically significant, and the interval cannot rule out either a real benefit or none.
The New England Journal of Medicine
In a 20-person ward trial, an ultra-processed menu led to more eating and weight gain
In 20 adults living in a hospital research unit for 28 days, an ultra-processed menu led them to eat 508 kcal/day more (± 106 SE, P = 0.0001) and gain 0.9 kg, while a menu of unprocessed foods led to a 0.9 kg loss, each over 2 weeks and with eating left to appetite. The study was small, short and fully provisioned, so it cannot show what happens in daily life or which feature of the foods drove the extra eating.
Cell Metabolism
Mediterranean diet with olive oil or nuts linked to fewer heart events (corrected trial)
Among 7447 Spanish adults aged 55 to 80 at high cardiovascular risk, those assigned to a Mediterranean diet with extra-virgin olive oil (HR 0.69, 95% CI 0.53 to 0.91) or with nuts (HR 0.72, 0.54 to 0.95) had fewer major cardiovascular events than those told to cut dietary fat. The trial had randomisation errors, which is why the 2013 report was withdrawn and the estimates recalculated, so treat this as strong but imperfect evidence.
The New England Journal of Medicine

